Suggestions
Christopher Rudd
Professeur, Université de Montreal
Christopher E. Rudd is a distinguished immunologist and researcher with a focus on T-cell signaling and cancer immunotherapy. He currently holds several academic positions:
Academic Appointments
- Full-time Professor (accredited) at Université de Montréal in the Department of Microbiology, Infection and Immunology13
- Adjunct Professor in the Department of Medicine at McGill University24
- Full member of the McGill Centre for Translational Research in Cancer12
Research Focus
Dr. Rudd's research primarily concentrates on:
- Receptors and signaling pathways of T-cells in the immune system
- Control of T-cell reactivity and tumor rejection
- Identification of key mediators in T-cell function for cancer treatment
His lab has made significant contributions to the field, including:
- Discovery of CD4 and CD8-p56lck complexes and adaptor proteins
- Identification of pathways for CD28, CTLA-4, and ICOS co-receptor function
- Laying the foundation for chimeric antigen receptor (CAR) cancer therapy
- Identifying glycogen synthase kinase (GSK-3) as a central regulator of PD-1 expression on T cells1
Education and Career
Dr. Rudd received his BSc from McGill University in Canada and his Ph.D. and D.Sc. degrees from University College London in the UK.7 He has had a distinguished career in immunology research, holding various positions before his current roles at Université de Montréal and McGill University.
Honors and Affiliations
Christopher E. Rudd holds several prestigious titles:
- FRCPath (Fellow of the Royal College of Pathologists)
- FMedSci (Fellow of the Academy of Medical Sciences)
- FRSC (Fellow of the Royal Society of Canada)5
His LinkedIn profile, under the username chrudd, indicates that he is based in Montréal-Ouest and has over 500 connections in his professional network.6
Highlights
Our humble contribution to the COVID-19 field. A super collaboration involving colleagues Drs. Richard Kremer and Catalin Mihalcioiu at McGill University Health Centre (MUHC) and the CR-HMR. Late but it makes a novel contribution by showing that within the MUHC patient population infected with SARs CoV-2, the severity of disease was linked to the preferential loss of TCF1+ stem-like progenitor T-cells needed to replenish the peripheral immune response. In our model, the cytokine storm leads to the preferential loss of progenitor CD4 and CD8 T-cells marked by either the loss of TCF1+ cells or their capacity to divide and expand. Few progenitors in the immune system= no protective immunity.
It’s been a while since I’ve completed my program at University of Cambridge, but I wanted to share this update with everyone.
